The event was attended by the President of the Government, Pedro Sánchez, the Minister of Industry and Tourism, Jordi Hereu, and other political authorities and company executives. This new 80,000 square meter plant represents an initial investment of 160 million euros and is considered key to strengthening the continent's strategic autonomy in plasma-derived medicines.

The Vice President of Grifols' board of directors, Raimon Grifols, highlighted that the new facility symbolizes the company's commitment to growth from the territory, with an industrial vision serving patients. The plant will increase production capacity in Catalonia, reaching three million liters of fractionated plasma annually.

The new complex, located in Lliçà de Vall (Barcelona), near its current factory in Parets del Vallès, will be part of a 25-hectare biotechnology 'hub'. This center will employ 3,700 people, with 400 new jobs directly related to the new facilities.

The infrastructure will include a plant for plasma fractionation, logistics operations, an analysis laboratory, and warehouses. Grifols emphasizes that this investment is part of its commitment to creating economic and social value, generating over 16,000 indirect jobs in Spain and contributing more than 1.5 billion euros to the economy.